Advaxis's Cancer Immunotherapy Featured on Fox News

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis's Cancer Immunotherapy Featured on Fox News

PRINCETON, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary Lm -LLO immunotherapy, was featured on Fox News Philadelphia in a segment focused on how dogs battling osteosarcoma (bone cancer) can help lead research for treating osteosarcoma and breast cancer in humans. ADXS-cHER2 is designed to teach the immune system to target the Her2 receptor, which is overexpressed in certain cancers, such as canine and human bone cancer and breast cancer.

The full Fox News segment can be accessed via the following URL: http://www.myfoxphilly.com/clip/10623350/dog-...he-disease .

The Fox broadcast segment, hosted by Karen Hepp, includes an interview with Dr. Nicola Mason, Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Mason is the principle investigator on two clinical trials evaluating the safety and efficacy of ADXS-cHER2 in canine osteosarcoma. In the first study, ADXS-cHER2 is being evaluated to determine whether it can prevent the spread of osteosarcoma in dogs that have undergone amputation and chemotherapy (the standard of care for dogs with osteosarcoma). This study is ongoing and the preliminary data is encouraging. The second study evaluates whether ADXS-cHER2 can be combined with radiation therapy to treat the primary tumor as well as prevent spread of the disease into the lungs and prolong overall survival without the need for amputation.

Dr. Mason commented, "ADXS-cHER2 is incredibly exciting and encouraging. We are hoping that this will not only be a cancer immunotherapy to treat dogs and prevent metastatic disease in dogs, but that it will be able to be rapidly translated into the human field, particularly into children that develop the same cancer as dogs do, osteosarcoma." 

Daniel J. O'Connor, President and Chief Executive Office of Advaxis, commented, "Dr. Mason's research is promising not only as a potential treatment for pet dogs, but also for children and young adults with osteosarcoma, as well as other Her2-overexpressing cancers such as breast, gastric and esophageal. We look forward to advancing ADXS-cHER2 into the clinic for pediatric osteosarcoma, as well as working alongside our partner, Aratana Therapeutics (Nasdaq: PETX ), to develop and commercialize ADXS-cHER2 for the treatment of osteosarcoma in pet dogs."

As highlighted in the Fox broadcast, most dogs with the disease die within a year of diagnosis, however, some of the dogs treated in Dr. Mason's first clinical study with ADXS-cHER2 are still alive after two years. Preliminary results showed that ADXS-cHER2 was able to delay or prevent metastatic disease and prolong overall survival in dogs with osteosarcoma that had minimal residual disease following the standard treatment of amputation and chemotherapy. As reported by Dr. Mason at The American College of Veterinary Internal Medicine Forum, 80% of the dogs treated (n=15) were still alive and median survival had not yet been reached; median survival in case-matched control dogs (n=13) was 316 days. Immunological analyses are also being conducted in this study to further evaluate the immune response to ADXS-cHER2.

About ADXS-cHER2

ADXS-cHER2 is an Lm -LLO immunotherapy for Her2 overexpressing cancers (such as osteosarcoma, breast, gastric and other cancers in humans and for osteosarcoma in canines). ADXS-cHER2 secretes the cHer2 antigen, fused to LLO, directly inside the APC that are capable of driving a cellular immune response to Her2 overexpressing cells. In preclinical analysis, localized effect is the inhibition of the Treg and MDSC cells that we believe may promote immunologic tolerance of the Her2 overexpressing cancer cells of the tumor.

About Canine Osteosarcoma

Osteosarcoma is the most common primary bone tumor in dogs, accounting for roughly 85% of tumors on the canine skeleton. Approximately 8,000-10,000 dogs a year (predominately middle to older-aged dogs and larger breeds) are diagnosed with osteosarcoma in the United States. This cancer initially presents as lameness and oftentimes visible swelling on the leg. Current standard of care treatment is amputation immediately after diagnosis, followed by chemotherapy and sometimes radiation for palliative care. Invariably, however, the cancer metastasizes to the lungs, eventually leading to death.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registration clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cervical cancer and head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1/2 clinical study with ADXS-PSA alone and in combination with a PD-1 checkpoint inhibitor. Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc.

For more information please visit www.advaxis.com or connect with us on

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Advaxis Contact: Lisa Caperelli Senior Director of Investor Relations and Corporate Communications Advaxis, Inc. 215.206.1822 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 112

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 140

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 109

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 100

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 111

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading

Top 5 Most Recently Viewed Articles

SiriusPoint Declares Cash Dividend on Series B Preference Shares

Updated Category News Views 123

SiriusPoint Declares Quarterly Cash Dividend for Investors In a significant move for its shareholders, SiriusPoint Ltd. has recently revealed the approval of a quarterly cash dividend of $0.50 per share for the 8.00% Resettable Fixed Rate Preference Shares, Series B. This decision, endorsed by the Audit Committee of the Board of Directors, showcases the company's...

Continue Reading
Urban One Welcomes New Leadership as CEO David Kantor Retires

Updated Category News Views 435

Changes in Leadership at Urban One Urban One has made a significant announcement regarding changes at the helm of its audio division. Currently, the company bids farewell to CEO David Kantor, a well-respected figure in the industry, whose tenure has shaped Urban One into a key player in audio entertainment. Kantor's retirement, set for early 2025, opens the door for new...

Continue Reading
Mattamy Homes Expands Presence with New Division in Florida

Updated Category News Views 502

Mattamy Homes Expands Operations in Florida Company strengthens regional focus to enhance customer service, empower teams and drive future expansion Mattamy Homes US has officially launched a new division centered in Southwest Florida. This strategic initiative is set to improve operational agility, allowing Mattamy to provide exceptional service to its customers...

Continue Reading
Eloro Resources Secures $3.78 Million in Latest Placement

Updated Category News Views 235

Eloro Resources Completes Private Placement Successfully Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) has announced a significant achievement in its funding efforts. The company successfully closed its non-brokered private placement offering, concluding with a total of 4,200,000 units sold. This move resulted in gross proceeds of approximately $3,780,000,...

Continue Reading
Groundbreaking Global Health Exhibition Set to Transform Healthcare

Updated Category News Views 54

Global Health Exhibition Promises Unmatched Innovation Tomorrow marks the opening of the much-anticipated Global Health Exhibition, an international healthcare event attracting over 100,000 professionals dedicated to health and patient care. Spanning across three days, this premier event will host an impressive assembly of over 1,200 exhibiting companies and brands,...

Continue Reading